https://doi.org/10.4081/monaldi.2026.3873
Fractional exhaled nitric oxide in non-cystic fibrosis bronchiectasis: an exploratory prospective observational study
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 24 July 2026
Published: 13 October 2026
Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of type 2 airway inflammation, but its role in non-cystic fibrosis bronchiectasis remains uncertain. This study explored the associations of FeNO with peripheral blood eosinophils, pulmonary function, high-resolution computed tomography (HRCT)-defined morphology, and short-term post-treatment change in adults with non-cystic fibrosis bronchiectasis. We conducted an exploratory prospective observational study including 152 adults with clinically and HRCT-confirmed non-cystic fibrosis bronchiectasis admitted to a national tertiary pulmonary center. FeNO was measured using a standardized single-flow technique. Pulmonary function testing, blood eosinophil assessment, and HRCT evaluation were performed. Descriptive statistics, between-group comparisons, correlation analyses, and exploratory multivariable linear regression were used. A subgroup underwent repeat FeNO assessment after antibiotic treatment. Mean FeNO was 12.1±7.9 ppb. FeNO correlated positively with blood eosinophil percentage (r=0.41, p<0.001) and MEF50% predicted (r=0.48, p<0.001) and inversely with total lung capacity % predicted (r=−0.39, p<0.001). FeNO distributions differed across ventilatory patterns (overall Kruskal-Wallis p=0.030) and HRCT morphology groups (overall Kruskal–Wallis p=0.040); the exploratory cylindrical versus cystic/saccular comparison yielded p=0.023 (unadjusted). In exploratory multivariable regression, blood eosinophil percentage remained associated with FeNO (β=1.12, 95% confidence interval: 0.29-1.95; p=0.009). Among 55 reassessed patients, FeNO decreased from 12.1±6.8 to 7.0±3.1 ppb after antibiotic treatment (p=0.010). FeNO was generally low in adults with non-cystic fibrosis bronchiectasis but showed exploratory associations with eosinophilic inflammation, selected pulmonary function parameters, HRCT morphology, and short-term post-treatment change. Larger longitudinal studies with standardized severity classification, microbiological characterization, and predefined outcomes are needed before FeNO can be recommended for routine clinical use.
Downloads
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017;50:1700629. DOI: https://doi.org/10.1183/13993003.00629-2017
Chalmers JD, Chang AB, Chotirmall SH, et al. Bronchiectasis. Nat Rev Dis Primers 2018;4:45. DOI: https://doi.org/10.1038/s41572-018-0042-3
Choi H, McShane PJ, Aliberti S, Chalmers JD. Bronchiectasis management in adults: state of the art and future directions. Eur Respir J 2024;63:2400518. DOI: https://doi.org/10.1183/13993003.00518-2024
Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016;47:1113-22. DOI: https://doi.org/10.1183/13993003.01899-2015
Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15. DOI: https://doi.org/10.1164/rccm.9120-11ST
Horvath I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J 2017;49:1600965. DOI: https://doi.org/10.1183/13993003.00965-2016
Chen YF, Hou HH, Chien N, et al. Type 2 biomarkers and their clinical implications in bronchiectasis: a prospective cohort study. Lung 2024;202:695-709. DOI: https://doi.org/10.1007/s00408-024-00707-0
Campisi R, Nolasco S, Mancuso M, et al. Eosinophilic bronchiectasis: prevalence, severity, and associated features—a cohort study. J Clin Med 2024;13:4932. DOI: https://doi.org/10.3390/jcm13164932
Shoemark A, Shteinberg M, De Soyza A, et al. Characterization of eosinophilic bronchiectasis: a European multicohort study. Am J Respir Crit Care Med 2022;205:894-902. DOI: https://doi.org/10.1164/rccm.202108-1889OC
Martinez-Garcia MA, Mendez R, Olveira C, et al. The U-shaped relationship between eosinophil count and bronchiectasis severity: the effect of inhaled corticosteroids. Chest 2023;164:606-13. DOI: https://doi.org/10.1016/j.chest.2023.04.029
Kharitonov SA, Wells AU, O'Connor BJ, et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995;15:1889-93. DOI: https://doi.org/10.1164/ajrccm.151.6.7767536
Shoemark A, Devaraj A, Meister M, et al. Elevated peripheral airway nitric oxide in bronchiectasis reflects disease severity. Respir Med 2011;105:885-91. DOI: https://doi.org/10.1016/j.rmed.2011.01.015
Tsikrika S, Dimakou K, Papaioannou AI, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine 2017;99:281-6. DOI: https://doi.org/10.1016/j.cyto.2017.08.005
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax 2019;74:1-69. DOI: https://doi.org/10.1136/thoraxjnl-2018-212463
Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60:2101499. DOI: https://doi.org/10.1183/13993003.01499-2021
Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index: an international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85. DOI: https://doi.org/10.1164/rccm.201309-1575OC
Martinez-Garcia MA, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014;43:1357-67. DOI: https://doi.org/10.1183/09031936.00026313
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296. DOI: https://doi.org/10.1371/journal.pmed.0040296
Keir HR, Shoemark A, Dicker AJ, et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respir Med 2021;9:873-84. DOI: https://doi.org/10.1016/S2213-2600(20)30504-X
Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186:657-65. DOI: https://doi.org/10.1164/rccm.201203-0487OC
Chen F, Zeng Z, Huang X, Liu Y. Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis. Chron Respir Dis 2023;20:14799731231210559. DOI: https://doi.org/10.1177/14799731231210559
Aliberti S, Sotgiu G, Blasi F, et al. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J 2020;56:2000453. DOI: https://doi.org/10.1183/13993003.00453-2020
Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med 2023;11:637-49. DOI: https://doi.org/10.1016/S2213-2600(23)00093-0
Ethics Approval
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.